CYTOXAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cytoxan, and when can generic versions of Cytoxan launch?
Cytoxan is a drug marketed by Baxter Hlthcare and is included in two NDAs.
The generic ingredient in CYTOXAN is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cytoxan
A generic version of CYTOXAN was approved as cyclophosphamide by BAXTER HLTHCARE on May 21st, 2008.
Summary for CYTOXAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 95 |
Clinical Trials: | 997 |
Patent Applications: | 4,412 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CYTOXAN at DailyMed |
Recent Clinical Trials for CYTOXAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Adam Kittai | Phase 2 |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2 |
Janssen Research & Development, LLC | Phase 2 |